内镜下射频消融术治疗胃低级别上皮内瘤变的临床研究

目的通过临床大样本研究,进一步明确内镜下射频消融术(RFA)治疗胃低级别上皮内瘤变(LGIN)的有效性及安全性。 方法回顾性选择2014年10月至2019年12月经解放军总医院消化内镜中心术前筛查的175例患者证实为胃LGIN的255例病变纳入研究,并进行内镜下RFA,关注其围手术期并发症发生情况,术后采用Wong-Baker面部表情量表进行疼痛评分,并追踪其复查随访结果。 结果255例病变均成功完成内镜下RFA,术中无明显并发症发生;术后3个月、6个月、1年、2年、3年的治愈率分别为91.3%、90.8%、89.4%、88.2%、86.5%,术后腹痛为主要并发症。 结论内镜下RFA是治疗胃LGIN的一种安全有效、操作简便、可门诊治疗的新方法,具有良好的临床应用前景。     

胃镜下无恶变征象的胃巨大溃疡145例诊疗分析

目的探讨胃镜下无恶变征象的胃巨大溃疡的发病趋势和特点、诊断性治疗的价值、内镜诊断与病理诊断的相关性。方法收集2005～2013年间胃镜诊断胃巨大溃疡、无典型恶变特征、且首次活检病理未报告"癌"的住院患者145例,均接受抗溃疡加抗幽门螺旋杆菌(Helicobacter pylori,H.pylori)四联疗法,分析其多次胃镜检查的转归及病理诊断的变化。结果胃镜下无恶变征象的胃巨大溃疡年均检出率为5.63%,无明显增高趋势,男性明显高于女性;总恶变率为45.52%,其恶变与性别、部位、大小和形态无相关性(P0.05),但与年龄、H.pylori感染相关(P0.01)。2次胃镜诊断巨大溃疡与病理诊断符合率分别为55.86%和98.62%。结论胃镜下无恶变征象胃巨大溃疡的恶变与性别、部位、大小和形态无关,但与H.pylori感染正相关,且41～70岁年龄段高发,诊断性治疗联合多次胃镜活检是其定性诊断的最佳方法。     

Long non-coding RNA OIP5-AS1 promotes the growth of gastric cancer through the miR-367-3p/HMGA2 axis

Increasing evidence shows that aberrant lncRNAs expression contributes to the progression of gastric cancer (GC). The role of the novel lncRNA OIP5-AS1 and its underlying mechanisms in the growth of GC is largely unknown. Here we demonstrate for the first time that OIP5-AS1 expression was up-regulated in GC tissues and cell lines, which significantly correlated with unfavorable clinical characteristics and shorter survival. The results of in vitro and in vivo gain- and loss-of-function experiments indicate that OIP5-AS1 promoted cell proliferation and colony formation while inhibiting apoptosis of GC cells. OIP5-AS1 functioned as an endogenous sponge for miR-367-3p in GC cells. Restoration of miR-367-3p expression abolished the biological effects of OIP5-AS1 on GC cells. Moreover, we show that HMGA2 was a downstream target of miR-367-3p and mediated the effects of OIP5-AS1 on GC cells. OIP5-AS1 regulated the activities of the PI3K/AKT and Wnt/β-catenin pathways through HMGA2. In conclusion, OIP5-AS1 functions as an oncogenic lncRNA that promotes the progression of GC and may serve as a therapeutic target for managing GC.     

Impact of Anti-Aggregant,Anti-Coagulant and Non-Steroidal Anti-Inflammatory Drugs on Hospital Outcomes in Patients with Peptic Ulcer Bleeding

Background/Aims:

There are a limited number of studies including the impact of antiplatelet drugs use on hospital outcomes for nonvariceal upper gastrointestinal bleeding. The aim of this study was to determine the effect of anti-aggregant, anti-coagulant and non-steroidal anti-inflammatory drugs upon hospital outcomes in patients with peptic ulcer bleeding.

Materials and Methods:

The patients under treatment with antiaggregant, anticoagulant or non-steroidal anti-inflammatory drugs were categorized as exposed group (n = 118) and the patients who were not taking any of these drugs were categorized as non-exposed group (n = 81). We analyzed the data of drug intake, comorbid disease, blood transfusion, duration of hospital stay, Blatchford/total Rockall score and diagnosis of patients.

Results:

In total, 199 patients were included. Of these 59.3% (exposed group) were taking drugs. The patients in exposed group were significantly older than those in non-exposed group (62.9 ± 17.3 years; 55.5 ± 19.3 years, P = 0.005, respectively). Mean number of red blood cell units transfused (2.21 ± 1.51; 2.05 ± 1.87, P = 0.5), duration of hospital stay (3.46 ± 2.80 days; 3.20 ± 2.30 days, P = 0.532) and gastric ulcer rate (33% vs 23.4%, P = 0.172) were higher in exposed group than in non-exposed group but the differences were not statistically significant. Total Rockall and Blatchford scores of the patients were significantly higher in exposed group than in non-exposed group (3.46 ± 1.72 vs 2.94 ± 1.87, P = 0.045; 10.29 ± 3.15 vs 9.31 ± 3.40, P = 0.038).

Conclusıon:

Our study has shown that anticoagulants, antiaggregants and nonsteroidal anti-inflammatory drugs do not effect duration of hospital stay, red blood cell transfusion requirement and rebleeding for peptic ulcer bleeding.     

养肝生肌汤治疗糖尿病足溃疡的临床疗效观察

目的探讨针对糖尿病足溃疡患者实施养肝生肌汤治疗的方法及疗效。方法选择该院于2016年12月—2018年12月期间收治的糖尿病足溃疡患者作为资料,共102例随机分组,对照组和观察组分别采用常规西医治疗和增加中医养肝生肌汤治疗,各51例,观察两组治疗效果。结果观察组治疗有效率为96.08%,对照组为80.39%,比较差异有统计学意义(P<0.05);治疗后,观察组足背动脉内径和血流速度明显提升,且与对照组比较明显更高,差异有统计学意义(P<0.05);治疗后,观察组氧化应激及炎症指标AOPPs、FGF2、TNF-α、IL-6明显改善,且显著优于对照组,差异有统计学意义(P<0.05)。结论在糖尿病足溃疡治疗中应用中药养肝生肌汤治疗对促使症状消失,缓解疼痛有明显作用,确保恢复正常活动能力,对减轻炎症及氧化应激反应有良好效果,且可改善足背血流,提高生活质量,治疗价值较高。     

多烯磷脂酰胆碱联合双环醇治疗胃癌化疗导致的药物性肝损伤患者疗效及其对血清细胞因子和氧化应激指标水平的影响

目的 探讨应用多烯磷脂酰胆碱联合双环醇治疗胃癌化疗所致的药物性肝损伤(DILI)患者疗效及其对血清细胞因子和氧化应激指标的影响。方法 2017年5月～2019年5月我院收治的胃癌根治术后患者78例,给予奥沙利铂、多西他赛和氟尿嘧啶化疗。在化疗过程中出现DILI患者40例,被随机分为对照组(n=19)和观察组(n=21),给予对照组患者多烯磷脂酰胆碱治疗,给予观察组多烯磷脂酰胆碱联合双环醇片治疗,两组均观察4周。采用ELISA法检测血清肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6),采用硫代巴比妥酸法检测血清丙二醛(MDA),采用黄嘌呤氧化法检测血清超氧化物歧化酶(SOD)。采用卡氏功能状态(KPS)量表评估患者生存质量。结果 在治疗4周末,观察组血清丙氨酸氨基转移酶(ALT)水平为(33.5±7.9)U/L,显著低于对照组【(42.4±8.8)U/L,P<0.05】,血清天冬氨酸氨基转移酶(AST)水平为(34.4±5.7)U/L,显著低于对照组【(39.4±6.2)U/L,P<0.05】,血清碱性磷酸酶(ALP)水平为(60.6±14.2)U/L,显著低于对照组【(75.3±16.6)U/L,P<0.05】,而KPS评分为(64.1±17.2)分,显著高于对照组【(48.3±14.5)分,P<0.05】;联合组肝功能复常率为81.0%,显著高于对照组的63.2%(P<0.05);观察组血清TNF-α水平为(15.2±2.1)mg/L,显著低于对照组【(21.4±3.6)mg/L,P<0.05】,血清IL-6水平为(28.1±4.5)pg/mL,显著低于对照组【(46.2±5.9)pg/mL,P<0.05】;血清MDA水平为(5.1±0.8)nmol/mL,显著低于对照组【(5.9±0.7)nmol/mL,P<0.05】,而血清SOD水平为(2.3±0.5)U/mL,显著高于对照组【(1.8±0.4)U/mL,P<0.05】。结论 联合应用多烯磷脂酰胆碱和双环醇片治疗化疗药导致的DILI患者能改善肝功能,可能与抑制了氧化应激反应,降低了血清细胞因子水平有关,值得进一步研究。